HCPLive Network

Despite Combined Antiretroviral Treatment, Anal Cancer Risk Still High for HIV-Infected

 
THURSDAY, Dec. 13 (HealthDay News) -- For HIV-infected patients, despite combined antiretroviral treatment (cART), the risk of anal cancer is still much higher than in the general population, according to a study published in the Dec. 10 issue of the Journal of Clinical Oncology.

Christophe Piketty, M.D., Ph.D., from the Hôpital Européen Georges Pompidou in Paris, and colleagues compared the incidence rates of anal cancer across four time periods: 1992 to 1996 (pre-cART); 1997 to 2000 (early cART); and 2001 to 2004 and 2005 to 2008 (both recent cART). During these periods, 263 cases of histologically confirmed invasive anal squamous cell carcinoma were identified.

The researchers found that, for HIV-infected patients, the hazard ratio for anal cancer was 2.5 in the cART periods versus the pre-cART period, with no difference noted across the cART calendar periods. In 2005 to 2008, compared with the general population, for HIV-infected patients there was an excess risk of anal cancer with a standardized incidence ratio of 109.8 for men who have sex with men (MSM), 49.2 for other men, and 13.1 for women. For patients with CD4 counts above 500/µL for at least two years, the standardized incidence ratios were 67.5 and 24.5, respectively, when the CD4 nadir was less than 200/µL for more than two years or more than 200/µL.

"Relative to that in the general population, the risk of anal cancer in HIV-infected patients is still extremely high, even in patients with high current CD4 cell counts," the authors write. "cART appears to have no preventive effect on anal cancer, particularly in MSM."
 

Abstract
Full Text (subscription or payment may be required)

 
Copyright © 2012 HealthDay. All rights reserved.
 

Further Reading
Researchers at Hong Kong University and the Wellcome Trust Sanger Institute have identified a link between the influenza A viruses’ genetic diversity and severity of the infection.
Carol Burke, MD, FACG, FASGE, talks about her phase-3 placebo-controlled trial of Celecoxib in pediatric subjects with familial adenomatous polyposis (FAP) at the 2014 ACG Annual Meeting in Philadelphia, PA.
Carol Burke, MD, FACG, FASGE, discusses pediatric familial adenomatous polyposis (FAP) and colorectal cancer at the 2014 ACG Annual Scientific Meeting in Philadelphia, PA.
Black women undergoing in vitro fertilization are only about half as likely as white women to become pregnant, and the racial disparity persists even when donor eggs are used. These findings are being presented at the annual meeting of the American Society for Reproductive Medicine, held from Oct. 18 to 22 in Honolulu.
Hospital conversion to for-profit status is associated with improvements in financial margins, but has no effect on process quality metrics or mortality rates, according to a study published in the Oct. 22/29 issue of the Journal of the American Medical Association
Drinking sugar-sweetened sodas may affect cellular aging by shortening telomere length, according to research published online Oct. 16 in the American Journal of Public Health.
Increasing use of hospice in the final days of ovarian cancer does not offset intensive end-of-life care in older women, according to a study published online Oct. 6 in the Journal of Clinical Oncology.
More Reading